Literature DB >> 11138608

New automated chemiluminescent assay for erythropoietin.

E W Benson1, R Hardy, C Chaffin, C A Robinson, R J Konrad.   

Abstract

Erythropoietin (EPO) is a polypeptide hormone produced by the kidney that regulates erythropoiesis by controlling the proliferation and differentiation of erythroid progenitors in bone marrow. Assays for EPO are used to monitor dosage and response to human recombinant erythropoietin also may have diagnostic utility in the differential diagnosis of anemia and polycythemia. We evaluated an automated, chemiluminescent immunoassay for EPO (DPC Immulite) in terms of precision, linearity, interference, and correlation with reference assays. The Immulite assay demonstrated acceptable correlation with the reference immunochemiluminometric method (slope = 1.087, y intercept = 0.567, R value = 0.990). Within-run CVs ranged from 2.3% to 5.0%, while between-run CVs ranged from 4.1% to 9.5%. Linearity extended beyond the manufacturer's stated claims, and recovery ranged from 96.8% to 100.9% across the concentrations tested. No significant interference was noted with hemoglobin, bilirubin, or triglyceride. Overall, this method compares favorably with the existing immunochemiluminometric reference method and offers clinical laboratories an alternative for the analysis of erythropoietin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138608      PMCID: PMC6807768          DOI: 10.1002/1098-2825(20001212)14:6<271::aid-jcla4>3.0.co;2-8

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  8 in total

1.  Rapid and sensitive method for erythropoietin determination in serum.

Authors:  M Tanebe; S Teshima; T Hanyu; Y Hayashi
Journal:  Clin Chem       Date:  1992-09       Impact factor: 8.327

2.  Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.

Authors:  J T Marsden; R A Sherwood; A Hillis; T J Peters
Journal:  Ann Clin Biochem       Date:  1993-03       Impact factor: 2.057

3.  Evaluation of six erythropoietin kits.

Authors:  J T Marsden; R A Sherwood; T J Peters
Journal:  Ann Clin Biochem       Date:  1999-05       Impact factor: 2.057

Review 4.  Diagnosing polycythemia vera: a paradigm shift.

Authors:  A Tefferi
Journal:  Mayo Clin Proc       Date:  1999-02       Impact factor: 7.616

5.  In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia.

Authors:  L Y Shih; C T Lee; L C See; Y C Ou; P Dunn; P N Wang; M C Kuo; J H Wu
Journal:  Eur J Clin Invest       Date:  1998-07       Impact factor: 4.686

Review 6.  Are current methods of measurement of erythropoietin (EPO) in human plasma or serum adequate for the diagnosis of polycythaemia vera and the assessment of EPO deficiency?

Authors:  G Lindstedt; P A Lundberg
Journal:  Scand J Clin Lab Invest       Date:  1998-10       Impact factor: 1.713

7.  Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment.

Authors:  G Birgegård; L Wide
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

8.  Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.

Authors:  J Carneskog; J Kutti; H Wadenvik; P A Lundberg; G Lindstedt
Journal:  Eur J Haematol       Date:  1998-05       Impact factor: 2.997

  8 in total
  7 in total

1.  Anaemia predicts cardiovascular events in patients with stable coronary artery disease.

Authors:  E Lips̆ic; F W Asselbergs; P van der Meer; R A Tio; A A Voors; W H van Gilst; F Zijlstra; D J van Veldhuisen
Journal:  Neth Heart J       Date:  2005-08       Impact factor: 2.380

Review 2.  Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level.

Authors:  Jaime Sanz Ortiz
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

3.  Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema.

Authors:  Hyun Jin Shin; Hyung Chan Kim; Jun Woong Moon
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

4.  Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.

Authors:  Andrea Inthal; Gerd Krapf; Dominik Beck; Ruth Joas; Max O Kauer; Lukas Orel; Gerhard Fuka; Georg Mann; E Renate Panzer-Grümayer
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

5.  Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.

Authors:  Eliane Nguyen; Michaël Harnois; Lambert Busque; Shireen Sirhan; Sarit Assouline; Ines Chamaki; Harold Olney; Luigina Mollica; Natasha Szuber
Journal:  Blood Cancer J       Date:  2021-04-15       Impact factor: 11.037

6.  Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates.

Authors:  Niels Grote Beverborg; Niek Verweij; Ijsbrand T Klip; Haye H van der Wal; Adriaan A Voors; Dirk J van Veldhuisen; Ron T Gansevoort; Stephan J L Bakker; Pim van der Harst; Peter van der Meer
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

7.  Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

Authors:  Natasha Szuber; Sravanthi Lavu; Mythri Mudireddy; Maura Nicolosi; Domenico Penna; Rangit R Vallapureddy; Terra L Lasho; Christy Finke; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Naseema Gangat; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-11-19       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.